Colorectal Cancer :: New vaccine stimulates colorectal cancer patient’s immune systems to fight cancerous cells
British researchers have developed a vaccine that stimulates colorectal cancer patients’ immune systems to fight cancerous cells.
Colorectal cancer
Colorectal Cancer :: Studies examine colorectal cancer screening rates
The rate of colorectal cancer screening appears to be increasing among Veterans Affairs patients, although use of colonoscopy is less common than other screening procedures, according to a report in the Nov. 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. A second report in the same journal shows that younger veterans with other illnesses and reduced life expectancies may not necessarily benefit from such screening and may even be harmed, but continue to be screened at high rates.
Osteosarcoma :: IDM Pharma’s Mepact, mifamurtide – Junovan in the Treatment of Osteosarcoma
IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted a Marketing Authorization Application (MAA) in eCTD format (electronic common technical document) to the European Medicines Agency (EMEA) for Mepact (mifamurtide for injection), requesting approval for its use in the treatment of patients with newly diagnosed resectable high-grade osteosarcoma following surgical resection in combination with post-operative multi-agent chemotherapy. This announcement follows the October 25, 2006 submission of a New Drug Application (NDA) for Junovan (mifamurtide for injection) to the Food and Drug Administration (FDA) in the United States.
Colorectal Cancer :: Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
ImClone Systems Incorporated (NASDAQ:IMCL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced results from two randomized Phase III trials of ERBITUX(R) (cetuximab) in patients with metastatic colorectal cancer. These are the first large, randomized studies to examine the impact of ERBITUX treatment on overall survival in colon cancer.
Cancer :: Report calls for using heated chemotherapy after colon cancer surgery to optimize patient survival
There is new hope for some of the most seriously ill colon cancer patients today, following the release of a consensus statement by 72 leading oncology surgeons from 14 countries, including the United States. The Peritoneal Surface Malignancy Group (PSMG) has concluded that surgery, followed by heated chemotherapy delivered through the lower abdomen of the patient before leaving the operating room, may significantly increase the life expectancy for patients with Stage IV colorectal cancer.
Colorectal Cancer :: Low folate diets found to increase risk of colorectal cancer
A new study by scientists at the MUHC has revealed that a diet low in folate may increase the risk of developing colorectal cancer. Published in the scientific journal Cancer Research today, the study not only illustrates a way to prevent the disease but also provides further insight into the mechanisms of the disease, which could lead to novel therapies. Using animal models, the MUHC study is the first to demonstrate directly that diets low in folate cause colorectal cancer, and follows on the heels of earlier research by the same team that revealed how high folate diets can protect against heart disease.
High Fiber Diet :: High-fiber Diet May Be More Important for Men Than Women
A collaborative effort between the Arizona Cancer Center and the National Cancer Institute (NCI) to understand the influence of diet on recurrence of colorectal adenomas (polyps) a precursor to cancer indicates that a high-fiber diet may be more important for men than women. Although the reason for a sex difference is unknown, researchers suggest that it may be related to hormonal effects or the difference between the sexes in location of polyp formation.
Cancer :: Cancer survival rates improving with better treatment, early diagnosis
No doubt, a cancer diagnosis is frightening. But consider this: the number of cancer survivors continues to grow, thanks to improved treatments, new treatments and earlier diagnosis.
Osteosarcoma :: IDM Pharma’s Junovan, mifamurtide in the treatment of osteosarcoma
IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted an electronic New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Junovan(TM) (mifamurtide for injection), requesting approval for its use in the treatment of newly diagnosed resectable high grade osteosarcoma patients following surgical resection in combination with multiple agent chemotherapy.
Colorectal Cancer :: Mesalazine to prevent colorectal cancer in IBD
Speaking at a Ferring-sponsored symposium on the occasion of the 14th United European Gastroenterology Week (UEGW) congress, Christoph Gasche, Associate Professor of Medicine, Medical University of Vienna, Austria presented the findings of an in-vitro study which for the first time demonstrates a mode of action by which mesalazine may reduce the risk of colorectal cancer in Inflammatory Bowel Disease (IBD) patients.